Meningitis Vaccine

Meningococcal Vaccine: An Opening for Virulent Strains?

Published in TB and Outbreaks Week, September 13th, 1999

The new meningococcal vaccine soon to be deployed in the U.K. could have disastrous unintended consequences, two Oxford researchers warn.

The vaccine is proven to protect against Neisseria meningitidis serogroup C meningococci, the principal cause of severe meningitis. University of Oxford researchers Martin C.J. Maiden and Brian G. Spratt welcome its imminent introduction.

They nevertheless warn that introduction of the vaccine could provide an ecological niche for other, highly virulent meningococci against which the vaccine offers no protection.

"The introduction of any vaccine that targets only a fraction of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1999-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry